Author’s response to reviews

Title: PARP inhibition and the radiosensitizing effects of the PARP inhibitor ABT-888 in in vitro hepatocellular carcinoma models

Authors:
Clément Guillot (clementguillot84@gmail.com)
Vincent Favaudon (vincent.favaudon@curie.fr)
Zdenko Herceg (herceg@iarc.fr)
Charlotte Sagne (charlotte.sagne@gmail.com)
Sylvie Sauvaigo (sylvie.sauvaigo@lxrepair.com)
Philippe Merle (philippe.merle@inserm.fr)
Janet Hall (janet.hall@curie.fr)
Isabelle Chemin (isabelle.chemin@inserm.fr)

Version: 3 Date: 28 July 2014

Author’s response to reviews:

Dear Madam, Sir

Please find the response point by point to the editors requests for our paper entitled “PARP inhibition and the radiosensitizing effects of the PARP inhibitor ABT-888 in in vitro hepatocellular carcinoma models” by Guillot et al.

1). Availability of Supporting Data section:

We encourage authors whose supporting data are available in an open access repository to include an Availability of supporting data section in their manuscript, before the Competing interests and Authors’ contributions. The section should state the name of the repository in which your data is deposited and include a link to the dataset DOI. If all the supporting data are included as additional files the section should state this. If your manuscript has any supporting sequence data, microarray data, or proteomic data this must be deposited in the appropriate repository and a link to the dataset should be included in the Availability of supporting data section.
Deposition of other supporting data is encouraged. Through a special arrangement with LabArchives, LLC (http://www.labarchives.com/), authors submitting manuscripts to BioMed Central journals can obtain a complimentary subscription to LabArchives (http://www.labarchives.com/bmc) with an allotment of 100MB of storage. LabArchives is an Electronic Laboratory Notebook which enables scientists to share and publish data files in situ; you can then link your article to these data using the ?Availability of supporting data? section. Clinical data can be deposited if consent to do so was obtained before the study began, in which case a statement should be in the manuscript, or if the data is deposited in a repository in an anonymized form that complies with data protection/privacy laws. For more information on supporting data please see the following http://www.biomedcentral.com/about/supportingdata.

We do not have available supporting data.

2). Please could you clarify the source of the cells used in your study in your methods section.

Cell lines used in this study came from ATCC or were gifted by a scientist involved in the establishment of the line. We added all the information about the source of the cells in the methods section of our manuscript. Primary human hepatocytes were isolated from surgical liver specimens obtained during partial hepatectomy. We provided in the methods section a statement detailing ethical approval and consent.

Best regards,

Lyon 07.28.14
Dr Isabelle Chemin

Cancer Research Center of Lyon

Leader Team 16, Hepatocarcinogenesis and viral infection